Risk of Pulmonary Embolism During Mandibular Tori Removal
The risk of pulmonary embolism (PE) during mandibular tori removal is extremely low in routine cases, but high-risk patients require formal VTE risk assessment and prophylaxis based on established surgical thromboprophylaxis protocols.
Understanding the Baseline Risk
Mandibular tori removal is typically a short-duration outpatient oral surgery procedure. The inherent PE risk is minimal in healthy patients undergoing this elective procedure. However, recent evidence demonstrates that pulmonary complications can occur following mandibular surgery, with PE representing approximately 6% of pulmonary complications in mandibular fracture cases 1. While this data comes from trauma surgery (which carries higher risk than elective tori removal), it establishes that PE is a recognized complication in mandibular procedures.
A case report confirms that pulmonary thromboembolism can occur following long-duration maxillofacial surgeries, particularly in patients with multiple risk factors 2. The key distinction is that mandibular tori removal is typically much shorter in duration than panfacial reconstruction.
Risk Stratification Framework
High-Risk Patient Characteristics
You must assess for these specific VTE risk factors before surgery 3, 4:
- Age ≥55 years with additional risk factors
- Previous history of VTE (most critical factor)
- Active cancer or cancer treatment within 6 months
- Obesity (BMI ≥35 kg/m²) 1
- ≥3 comorbidities present simultaneously 1
- Congestive heart failure 1
- Coagulopathy or thrombophilia 1
- Peripheral vascular disorders 1
- Pulmonary circulation disorders 1
- Chronic respiratory disease 1
- Paralysis or neurological disorders 1
- Fluid and electrolyte disorders 1
- Prolonged immobility (wheelchair-bound, bedbound)
- Pregnancy or recent postpartum period (<6 weeks)
- Estrogen therapy or oral contraceptives
Surgical Duration Considerations
If the anticipated surgical time exceeds 30 minutes under general anesthesia, this constitutes a transient major risk factor for VTE 5. Most mandibular tori removals fall below this threshold, but bilateral extensive tori or complicated cases may exceed it.
Management Algorithm
For Low-Risk Patients (No Risk Factors Above)
- No pharmacological prophylaxis required
- Early mobilization immediately post-procedure
- Adequate hydration 3, 4
- Standard postoperative instructions
For High-Risk Patients
Implement prophylaxis immediately if any high-risk features are present 3, 4:
Mechanical prophylaxis (preferred for outpatient surgery):
- Apply thigh-high intermittent pneumatic compression (IPC) devices intraoperatively and in recovery
- Continue until patient is fully ambulatory
- Assess skin integrity if used beyond immediate perioperative period 3
Pharmacological prophylaxis:
- Low-molecular-weight heparin (LMWH) such as enoxaparin is first-line 3, 4
- Dose: Standard prophylactic dosing (e.g., enoxaparin 40 mg subcutaneous daily)
- Unfractionated heparin only if renal failure present (eGFR <30 mL/min) 3, 4
- Timing: Begin preoperatively or immediately postoperatively if no active bleeding
Duration of prophylaxis:
- For outpatient procedures: Continue until fully mobile (typically 24-48 hours)
- If patient has cancer or remains immobile >30 days: extend prophylaxis for 4 weeks post-surgery 6
Contraindications to Pharmacological Prophylaxis
Do not use anticoagulant prophylaxis if 3, 7:
- Active bleeding or recent hemorrhage
- Intracranial hemorrhage risk
- Severe uncontrolled hypertension
- Heparin-induced thrombocytopenia within past year
- Severe liver disease with coagulopathy
In these cases, use mechanical prophylaxis exclusively 3.
Critical Pitfalls to Avoid
Do not use anti-embolism stockings alone—they are ineffective for VTE prophylaxis 3, 4
Do not delay prophylaxis—if indicated, begin within 24 hours of surgery 3
Do not assume short procedures are risk-free in patients with multiple comorbidities—the patient's baseline risk matters more than procedure duration 1
Do not overlook occult cancer—unexplained VTE may be the first presentation of malignancy 5
For patients already on anticoagulation who develop PE perioperatively, this represents anticoagulation failure and requires immediate escalation of care 7
Postoperative Monitoring
Educate patients to recognize PE symptoms 8:
- Sudden-onset dyspnea
- Pleuritic chest pain
- Hemoptysis
- Syncope or presyncope
- Unexplained tachycardia
If PE is suspected postoperatively:
- Immediate emergency department evaluation
- Use validated clinical prediction rules (Wells score, Geneva score) 9
- D-dimer testing appropriate for low-intermediate probability patients 9
- CT pulmonary angiography for high probability or positive D-dimer 9
Special Populations
Patients with previous VTE: These patients have >8% annual recurrence risk 5 and should receive prophylaxis regardless of procedure duration. Consider continuing their baseline anticoagulation perioperatively with minimal interruption.
Patients with antiphospholipid syndrome: Require indefinite anticoagulation 5 and should not have therapy interrupted for elective tori removal without hematology consultation.
Patients on estrogen therapy: Consider temporary discontinuation 4 weeks before elective surgery if feasible, or ensure robust prophylaxis if continued 5.